Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interference with testing for lysergic acid diethylamide

D Ritter1, C M Cortese, L C Edwards

  • 1Pathology and Laboratory Medicine, John Cochran Veterans Affairs Medical Center, Saint Louis, MO 63106, USA. ritterdg@sluvca.slu.edu

Clinical Chemistry
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"The System is Overwhelming and Frustrating and Discouraging": Stress and Social Support for Affected Family Carers in an Unregulated Drug Crisis.

Substance use & misuse·2026
Same author

A nomogram based on radiological features and immunoscore for predicting meningioma recurrence.

Clinical radiology·2025
Same author

Der Nervenarzt·2025
Same author

Early autologous and/or allogeneic stem cell transplantation for adult patients with advanced stage T- lymphoblastic leukemia/lymphoma or Burkitt lymphoma. A retrospective single-centre analysis.

Annals of hematology·2024
Same author

[Relapse prevention of bipolar disorders: a cluster analytical approach in a randomized controlled psychotherapy study].

Der Nervenarzt·2024
Same author

[A survey on the implementation of cardiovascular surgery for congenital heart disease in China between 2017 and 2021].

Zhonghua yi xue za zhi·2024
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
Same journal

Editor's Note: Circulating Proteolytic Products of Carboxypeptidase N for Early Detection of Breast Cancer.

Clinical chemistry·2026
Same journal

In Reply to Reflexing NT-proBNP for sFlt-1/PlGF Ratios That Fall into the Measurement Uncertainty for Preeclampsia Risk Classification.

Clinical chemistry·2026
See all related articles

A common drug test for lysergic acid diethylamide (LSD) showed high false positive rates. Therapeutic medications interfered with the Emit assay, leading to inaccurate lysergic acid diethylamide (LSD) drug testing results.

Area of Science:

  • Forensic Toxicology
  • Analytical Chemistry
  • Clinical Chemistry

Background:

  • The Emit assay is widely used for drugs-of-abuse (DOA) screening.
  • Accurate detection of lysergic acid diethylamide (LSD) is crucial in clinical and forensic settings.
  • Potential interferences in DOA testing can compromise patient care and legal outcomes.

Purpose of the Study:

  • To investigate a high rate of positive results for lysergic acid diethylamide (LSD) using the Emit assay.
  • To identify the cause of false positive results in lysergic acid diethylamide (LSD) drug testing.
  • To assess the impact of therapeutic medications on Emit DOA assays.

Main Methods:

  • Analysis of 1898 urine samples using the Emit assay for lysergic acid diethylamide (LSD).

Related Experiment Videos

  • Confirmation of Emit-positive samples using two different radioimmunoassay (RIA) methods.
  • Gas chromatography-mass spectrometry (GC-MS) analysis of selected Emit-positive samples.
  • In vitro testing of urine samples supplemented with common therapeutic medications.

    • Main Results:

    • A high prevalence (4.2%) of false positive lysergic acid diethylamide (LSD) results was observed with the Emit assay.
    • Emit-positive samples consistently tested negative for lysergic acid diethylamide (LSD) by RIA and GC-MS.
    • Therapeutic medications commonly prescribed to psychiatric patients caused false positive lysergic acid diethylamide (LSD) results in the Emit assay.
    • Other Emit DOA tests were not affected by the tested therapeutic medications.

    Conclusions:

    • The Emit assay demonstrates poor specificity for lysergic acid diethylamide (LSD) detection in urine.
    • Therapeutic drug interference is a significant issue with the Emit assay for lysergic acid diethylamide (LSD).
    • Clinical laboratories should be aware of potential false positives and consider confirmatory testing for lysergic acid diethylamide (LSD).